Sorry, we do not have enough data to show an influence graph for this author.
- Full text PDF available (0)
Journals and Conferences
The approval of Provenge (Dendreon) in 2010 signaled the dawn of a new era in the development of active immunotherapeutics. For cancer treatment, the approval of Provenge® demonstrates that the immune system can effectively be harnessed to combat cancer. The outlook for active immunotherapies looks bright in terms of promising new approaches and candidates,… (More)